2126 related articles for article (PubMed ID: 19634161)
1. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
[TBL] [Abstract][Full Text] [Related]
2. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
Shin DM; Glisson BS; Khuri FR; Lippman SM; Ginsberg L; Diaz E; Papadimitrakopoulou V; Feng L; Francisco M; Garden A; Kies MS; Myers J; Clayman G; Hong WK
Cancer; 2002 Jul; 95(2):322-30. PubMed ID: 12124833
[TBL] [Abstract][Full Text] [Related]
5. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
Haraf DJ; Rosen FR; Stenson K; Argiris A; Mittal BB; Witt ME; Brockstein BE; List MA; Portugal L; Pelzer H; Weichselbaum RR; Vokes EE
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5936-43. PubMed ID: 14676118
[TBL] [Abstract][Full Text] [Related]
6. Chemoradiotherapy for advanced inoperable head and neck cancer: A phase II study.
Chougule PB; Akhtar MS; Akerley W; Ready N; Safran H; McRae R; Nigri P; Bellino J; Koness J; Radie-Keane K; Wanebo H
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):58-63. PubMed ID: 10210541
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
8. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
Schwartz DL; Montgomery RB; Yueh B; Donahue M; Anzai Y; Canby R; Buelna R; Anderson L; Boyd C; Hutson J; Keegan K
Cancer; 2005 Jun; 103(12):2534-43. PubMed ID: 15856475
[TBL] [Abstract][Full Text] [Related]
9. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
Rosen FR; Haraf DJ; Kies MS; Stenson K; Portugal L; List MA; Brockstein BE; Mittal BB; Rademaker AW; Witt ME; Pelzer H; Weichselbaum RR; Vokes EE
Clin Cancer Res; 2003 May; 9(5):1689-97. PubMed ID: 12738722
[TBL] [Abstract][Full Text] [Related]
10. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
[TBL] [Abstract][Full Text] [Related]
11. Preoperative paclitaxel, carboplatin, and radiation therapy in advanced head and neck cancer (stage III and IV).
Wanebo HJ; Chougule P; Ready N; Koness RJ; Akerley W; McRae R; Nigri P; Leone L; Webber B; Safran H
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):77-84. PubMed ID: 10210544
[TBL] [Abstract][Full Text] [Related]
12. [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
Vacha P; Marx M; Engel A; Richter E; Feyerabend T
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():18-22. PubMed ID: 10584135
[TBL] [Abstract][Full Text] [Related]
13. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
Leong SS; Tan EH; Fong KW; Wilder-Smith E; Ong YK; Tai BC; Chew L; Lim SH; Wee J; Lee KM; Foo KF; Ang P; Ang PT
J Clin Oncol; 2003 May; 21(9):1767-74. PubMed ID: 12721253
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma.
Amrein PC; Clark JR; Supko JG; Fabian RL; Wang CC; Colevas AD; Posner MR; Deschler DG; Rocco JW; Finkelstein DM; McIntyre JF
Cancer; 2005 Oct; 104(7):1418-27. PubMed ID: 16116597
[TBL] [Abstract][Full Text] [Related]
15. Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm.
Arnold SM; Regine WF; Ahmed MM; Valentino J; Spring P; Kudrimoti M; Kenady D; Desimone P; Mohiuddin M
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1411-7. PubMed ID: 15050317
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901
[TBL] [Abstract][Full Text] [Related]
17. Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 an 1999.
Dunphy FR; Dunleavy TL; Harrison BR; Trinkaus KM; Kim HJ; Stack BC; Needles B; Boyd JH
Cancer; 2001 Mar; 91(5):940-8. PubMed ID: 11251945
[TBL] [Abstract][Full Text] [Related]
18. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.
Hanna E; Alexiou M; Morgan J; Badley J; Maddox AM; Penagaricano J; Fan CY; Breau R; Suen J
Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):861-7. PubMed ID: 15262764
[TBL] [Abstract][Full Text] [Related]
19. Treatment of base of tongue cancer with paclitaxel, ifosfamide, and cisplatinum induction chemotherapy followed by chemoradiotherapy.
Hancock SB; Krempl GA; Canfield V; Bogardus C; Kojouri K; Kaneaster SK; Medina JE
Laryngoscope; 2008 Aug; 118(8):1357-61. PubMed ID: 18528311
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
